Alternative Data for Akero Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,141 | Sign up | Sign up | Sign up |
| X Followers | 458 | Sign up | Sign up | Sign up |
| X Mentions | 39 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 74 | Sign up | Sign up | Sign up |
About Akero Therapeutics
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States.
| Price | $54.65 |
| Target Price | Sign up |
| Volume | 15,310,000 |
| Market Cap | $4.5B |
| Year Range | $42.18 - $56.19 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Novo Nordisk releases 2026 sales and operating profit outlookFebruary 3 - GlobeNewswire |
|
MASLD as a complication of obesity must include liver risk stratificationJanuary 6 - Nature.com |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -82M | -80M | -0.990 |
| Q2 '25 | 0 | 0 | 0 | -71M | -69M | -0.860 |
| Q1 '25 | 0 | 0 | 0 | -71M | -70M | -0.900 |
| Q4 '24 | 4,000 | 2,000 | 2,000 | -70M | -69M | -0.990 |
| Q3 '24 | 0 | 1,000 | -1,000 | -73M | -71M | -1.050 |
Insider Transactions View All
| Cheng Andrew filed to sell 526,114 shares at $54. October 14 '25 |
| Rolph Timothy filed to sell 166,571 shares at $46.8. October 9 '25 |
| Rolph Timothy filed to sell 167,608 shares at $46. October 9 '25 |
| Young Jonathan filed to sell 196,898 shares at $48. October 3 '25 |
| Young Jonathan filed to sell 201,099 shares at $47.6. October 3 '25 |
Similar companies
Read more about Akero Therapeutics (AKRO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Akero Therapeutics
The Market Cap of Akero Therapeutics is $4.5B.
Currently, the price of one share of Akero Therapeutics stock is $54.65.
The AKRO stock price chart above provides a comprehensive visual representation of Akero Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Akero Therapeutics shares. Our platform offers an up-to-date AKRO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Akero Therapeutics (AKRO) does not offer dividends to its shareholders. Investors interested in Akero Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Akero Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
